Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2024 on Wednesday, March 12, 2025, After Close of U.S.-Based Financial Markets

Rhea-AI Summary

Nektar Therapeutics (NKTR) has scheduled its fourth quarter and full-year 2024 financial results announcement for Wednesday, March 12, 2025, after U.S. market close. The company will host a conference call at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time, led by President and CEO Howard Robin, to discuss the results.

The earnings call will be accessible through an audio-only webcast available on Nektar's investor relations website. The webcast recording will remain available for replay until April 12, 2025. Interested participants must pre-register through the Nektar Earnings Call Registration system to receive dial-in information and a PIN for call access.

SAN FRANCISCO, March 5, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the fourth quarter and year-ended December 31, 2024 on Wednesday, March 12, 2025, after the close of U.S.-based financial markets. Howard Robin, President and Chief Executive Officer, will host a conference call to review the results beginning at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time.

This press release and live audio-only webcast of the conference call can be accessed through a link that is posted on the Home Page and Investors section of the Nektar website: http://ir.nektar.com/. The web broadcast of the conference call will be available for replay through April 12, 2025.

To access the conference call, please pre-register at Nektar Earnings Call Registration. All registrants will receive dial-in information and a PIN allowing them to access the live call.

About Nektar Therapeutics

Nektar Therapeutics is a clinical-stage biotechnology company focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. Nektar's lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel, first-in-class regulatory T cell stimulator being evaluated in two Phase 2b clinical trials, one in atopic dermatitis and one in alopecia areata. Nektar's pipeline also includes a preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody and bispecific programs, NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422. Nektar, together with various partners, is also evaluating NKTR-255, an investigational IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer, in several ongoing clinical trials. Nektar is headquartered in San Francisco, California. For further information, visit www.nektar.com and follow Nektar on LinkedIn.

Contacts:

For Investors:
Vivian Wu of Nektar Therapeutics
(628) 895-0661

For Media:
Madelin Hawtin
LifeSci Communications
603-714-2638
mhawtin@lifescicomms.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/nektar-to-announce-financial-results-for-the-fourth-quarter-and-year-ended-2024-on-wednesday-march-12-2025-after-close-of-us-based-financial-markets-302393788.html

SOURCE Nektar Therapeutics

FAQ

When will Nektar (NKTR) release its Q4 and full-year 2024 earnings?

Nektar will release its Q4 and full-year 2024 earnings on Wednesday, March 12, 2025, after U.S. market close.

What time is Nektar's (NKTR) Q4 2024 earnings conference call?

The earnings call is scheduled for 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time on March 12, 2025.

How can investors access Nektar's (NKTR) Q4 2024 earnings call?

Investors must pre-register through the Nektar Earnings Call Registration system to receive dial-in information and access PIN.

How long will Nektar's (NKTR) Q4 2024 earnings call replay be available?

The earnings call webcast replay will be available until April 12, 2025, through Nektar's investor relations website.